{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:42:02Z","timestamp":1793108522218,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41375-026-03099-7","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:31:16Z","timestamp":1788175876000},"page":"2611-2615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography\u2013segmentation and a geriatric assessment"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0483-2560","authenticated-orcid":false,"given":"Samuel J.","family":"Yates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Terman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2131-1767","authenticated-orcid":false,"given":"John F.","family":"Cursio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Huisingh-Scheetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8774-5256","authenticated-orcid":false,"given":"Michael","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karteek","family":"Popuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza Faisal","family":"Beg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Akella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Youshanlouei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsheen","family":"Noorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-8356","authenticated-orcid":false,"given":"Caner","family":"Saygin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-8686","authenticated-orcid":false,"given":"Anand A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam T.","family":"Nawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8349-9200","authenticated-orcid":false,"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"3099_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:317\u2013629.","journal-title":"N Engl J Med"},{"key":"3099_CR2","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","volume":"145","author":"AH Wei","year":"2025","unstructured":"Wei AH, Loo S, Daver N. How I treat patients with AML using azacitidine and venetoclax. Blood. 2025;145:1237\u201350.","journal-title":"Blood"},{"key":"3099_CR3","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1200\/JCO.21.00195","volume":"39","author":"MA Flannery","year":"2021","unstructured":"Flannery MA, Culakova E, Canin BE, Peppone L, Ramsdale E, Mohile SG. Understanding treatment tolerability in older adults with cancer. J Clin Oncol. 2021;39:2150\u201363.","journal-title":"J Clin Oncol"},{"key":"3099_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood.2023022611","volume":"143","author":"VR Bhatt","year":"2024","unstructured":"Bhatt VR, Uy GL, Klepin HD. Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action. Blood. 2024;143:483\u20137.","journal-title":"Blood"},{"key":"3099_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","volume":"393","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393:2636\u201346.","journal-title":"Lancet"},{"key":"3099_CR6","doi-asserted-by":"publisher","first-page":"e068788","DOI":"10.1136\/bmj-2021-068788","volume":"377","author":"R Bernabei","year":"2022","unstructured":"Bernabei R, Landi F, Calvani R, Cesari M, Del Signore S, Anker SD, et al. Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project). BMJ. 2022;377:e068788.","journal-title":"BMJ"},{"key":"3099_CR7","doi-asserted-by":"crossref","unstructured":"Yates SJ, Abdallah NH, Christofyllakis K, VanderVeen BN, Pardee TS, Houston DK, et al. Sarcopenia in older adults with hematologic malignancies: a comprehensive review of epidemiology, prognosis, and interventions. Cancers. 2026;18:503.","DOI":"10.3390\/cancers18030503"},{"key":"3099_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.clnesp.2025.08.024","volume":"69","author":"M Salehin","year":"2025","unstructured":"Salehin M, Yang Chow VT, Lee H, Weltzien EK, Nguyen L, Li JM, et al. Validation of automated computed tomography segmentation software to assess body composition among cancer patients. Clin Nutr ESPEN. 2025;69:686\u201395.","journal-title":"Clin Nutr ESPEN"},{"key":"3099_CR9","doi-asserted-by":"crossref","unstructured":"Popuri K, Cobzas D, Esfandiari N, Baracos V, J\u00e4gersand M. Body composition assessment in axial CT images using FEM-based automatic segmentation of skeletal muscle. IEEE Trans Med Imaging. 2016;35:512\u201320.","DOI":"10.1109\/TMI.2015.2479252"},{"key":"3099_CR10","doi-asserted-by":"crossref","unstructured":"Venditti A, Palmieri R, Maurillo L, R\u00f6llig C, Wierzbowska A, de Leeuw DC, et al. Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of European Leukemia net. Blood Adv. 2025;9:2207\u201320.","DOI":"10.1182\/bloodadvances.2024013744"},{"key":"3099_CR11","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","volume":"41","author":"W Dale","year":"2023","unstructured":"Dale W, Klepin HD, Williams GR, Alibhai SMH, Bergerot C, Brintzenhofeszoc K, et al. Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update. J Clin Oncol. 2023;41:4293\u2013312.","journal-title":"J Clin Oncol"},{"key":"3099_CR12","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, DiNardo CD, Wei AH, L\u00f6wenberg B, Appelbaum F, Craddock C, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169\u201373.","DOI":"10.1182\/blood.2024025409"},{"key":"3099_CR13","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140:1345\u201377.","DOI":"10.1182\/blood.2022016867"},{"key":"3099_CR14","unstructured":"Williams B, Mandrekar J, Mandrekar S, Cha S, Furth A Technical report series No. 79, finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes, Department of Health Sciences Research. Mayo Clinic. 2006."},{"key":"3099_CR15","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.243525","volume":"315","author":"JM Zambrano Chaves","year":"2025","unstructured":"Zambrano Chaves JM, Hom J, Lenchik L, Chaudhari AS, Boutin RD. Sarcopenia, obesity, and sarcopenic obesity: retrospective audit of electronic health record documentation versus automated CT analysis in 17,646 patients. Radiology. 2025;315:e243525.","journal-title":"Radiology"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03099-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03099-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03099-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:58:48Z","timestamp":1793105928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03099-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3099"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03099-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"16 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AN, CS, CW, ET, HY, JFC, JM, LM, MHS, MTN, MZ, NF, SJY, and VA declare no conflicts of interest. AAP: Research Funding: Sumitomo, Pfizer, Incyte, Servier, Stemline. Honoraria: AbbVie, Amgen, Astellas, Cycle, Geron, Jazz, Novartis, Sobi, Syndax, Refined Oncology. Data Safety Monitoring Committee: Takeda. MFB and KP are co-founders and directors of Voronoi Health Analytics, Inc. (Vancouver, British Columbia, Canada), a medical imaging software company specializing in AI-powered body composition analysis. Statistical analyses and interpretation of study outcomes were conducted independent of these investigators to guard against conflict of interest. OO discloses research funding (paid to institution) from AbbVie, AstraZeneca, Celgene, Curis, Incyte, Shattuck Labs, and K-Group Alpha; scientific advisory board participation for AbbVie, Celgene\/Bristol Myers Squibb, Novartis, Incyte, Kymera Therapeutics, Servier, and Rigel; and service on data safety board for Treadwell Therapeutics. RAL has acted as a consultant or advisor to Ascentage Pharma, CVS\/Caremark, Epizyme\/Ipsen, and Novartis, and has received clinical research support to his institution from Ascentage, Astellas, Biomea Fusion, Cellectis, Daiichi Sankyo, and Novartis, and royalties from UpToDate. WS reports consultancy for Newave, Servier.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The UCCCC Institutional Review Board (IRB00000331) approved the study. All methods were performed in accordance with relevant ethical guidelines and regulations. All subjects provided informed consent.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}